文献速递神经肿瘤

非侵入性评估类淋巴系统改变作为胶质瘤总生存预测的潜在生物标志物

Noninvasive assessment of glymphatic system alterations as potential biomarkers for predicting overall survival in glioma.
PubMed 文献 · J Neurosurg · 2025-09-05

本研究基于UCSF-PDGM公共数据集,纳入437例成人弥漫性胶质瘤患者,通过MRI计算ALPS指数评估类淋巴系统功能。结果显示ALPS指数与肿瘤分级、IDH野生型及1p19q完整状态相关,较低ALPS指数与较短生存时间相关,且联合影像组学可改善生存预测。

要点

  • ALPS指数越低,胶质瘤患者总生存期越短(单因素Cox HR 0.297,95%CI 0.149-0.593,p<0.001)。
  • 高级别、IDH野生型和1p19q完整肿瘤患者类淋巴功能显著降低。
  • ALPS指数联合影像组学可提升生存预测C-index(训练队列0.709→0.711,验证队列0.675→0.693)。

核心结论

  • 较差的类淋巴系统功能与更具侵袭性的胶质瘤和更短的总生存时间相关。

研究设计与样本

  • 回顾性研究,使用UCSF-PDGM公共数据集,纳入501例成人弥漫性胶质瘤患者,最终分析437例。
  • 患者来自单中心2015至2021年,接受术前MRI、初始肿瘤切除和肿瘤基因检测。
  • 通过扩散图计算ALPS指数进行非侵入性类淋巴系统分析,并提取四个肿瘤区域的2288个影像组学特征。

主要发现

  • ALPS指数与周围FLAIR异常区形状特征MajorAxisLength相关性最强(r=-0.33,p<0.001)。
  • ALPS指数与强化区强度特征T2.RootMeanSquared相关(r=0.25,p<0.001)。
  • ALPS指数与坏死区形状特征Sphericity(r=0.26,p<0.001)和纹理特征FLAIR.glszm.GLNU(r=-0.24,p<0.001)相关。
  • 高级别肿瘤(p<0.001)、IDH野生型(p=0.01)和1p19q完整肿瘤(p=0.038)患者类淋巴功能降低。
  • 单因素Cox回归显示较低ALPS指数与较短生存时间相关(HR 0.297,95%CI 0.149-0.593,p<0.001)。

关键数值与推荐

  • 在组织学和分子亚组(4级、IDH野生型、1p19q完整)中,ALPS值低于中位数的患者总生存期显著更短。
  • ALPS指数联合影像组学使训练队列C-index从0.709升至0.711,验证队列从0.675升至0.693。
  • Kaplan-Meier分析中联合模型生存曲线区分度提高,p值从0.003降至0.0001。

临床怎么用

  • ALPS指数可作为非侵入性影像生物标志物,辅助评估胶质瘤侵袭性和预后。
  • 结合ALPS指数与影像组学特征可能改善胶质瘤患者生存预测。

局限性

  • 回顾性研究设计。
  • 单中心数据来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In this retrospective study, authors aimed to evaluate the glymphatic function alterations associated with glioma and explore the prognostic value of these alterations by calculating the index for diffusivity along the perivascular space (ALPS index). METHODS: The authors utilized data from the publicly available University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset, which includes 501 adult patients with histopathologically confirmed diffuse glioma, per the 2021 WHO classification, who underwent preoperative MRI, initial tumor resection, and tumor genetic testing at a single medical center from 2015 to 2021.The ALPS index was calculated from diffusivity maps for noninvasive glymphatic system (GS) analysis. The authors extracted 2288 radiomic features across four tumor regions: surrounding FLAIR abnormality, enhancing tumor, central nonenhancing and/or necrotic tumor, and whole tumor (combining necrosis, enhancement, and edema). For normally distributed variables (adjusted for age, enhancing tumor volume, and surrounding FLAIR abnormality volume), ANCOVA was utilized; nonnormally distributed data were analyzed using the Kruskal-Wallis test and Mann-Whitney U-test. Spearman's correlation coefficients were calculated to assess relationships between radiomic features and the ALPS index. Survival analysis included Kaplan-Meier curves, log-rank tests, concordance index (C-index), calibration and decision curves, and Cox regression. RESULTS: Ultimately, 437 patients with grade 2-4 gliomas were included in this study. The mean patient age was 57.46 ± 14.84 years, and 261 patients were male. The ALPS index correlated most strongly with shape features in the surrounding FLAIR abnormality region (MajorAxisLength, which measures elongation of the edema region, r = -0.33, p < 0.001), intensity features in the enhanced region (T2.RootMeanSquared, which quantifies variations in T2-weighted MRI signal intensity, r = 0.25, p < 0.001), and both shape and texture features in the necrotic region (Sphericity, which reflects the roundness of necrosis, r = 0.26, p < 0.001; FLAIR.glszm.GLNU, which reflects the uniformity of MRI signal distribution, r = -0.24, p < 0.001). Patients with higher-grade tumors (p < 0.001), IDH-wildtype glioma (p = 0.01), and 1p19q-intact tumors (p = 0.038) consistently exhibited reduced glymphatic function. Univariate Cox regression analysis demonstrated that a lower ALPS index was related to a shorter survival time (HR 0.297, 95% CI 0.149-0.593, p < 0.001). Subgroup analyses within histological and molecular subtypes (grade 4, IDH wildtype, and 1p19q intact) demonstrated that patients with ALPS values below the median had significantly shorter overall survival. The ALPS index combined with radiomics improved survival prediction, with the C-index increasing from 0.709 to 0.711 in the training cohort and from 0.675 to 0.693 in the validation cohort. Kaplan-Meier analysis further demonstrated more distinguishable survival curves, with the p value decreasing from 0.003 to 0.0001. CONCLUSIONS: Worse GS function was associated with more aggressive tumors and shorter survival times.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Li Q, Tao X, Li X, et al. Noninvasive assessment of glymphatic system alterations as potential biomarkers for predicting overall survival in glioma. J Neurosurg. 2025. PMID: 40911937. doi:10.3171/2025.5.JNS243268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。